Enhanced survival in antibiotic-treated murine fecal peritonitis by administration of copovithane, a selective immunostimulative polymer

Frederick L Moffat, A. G. Clark, M. Falk, J. A. Teodorczyk-Injeyan, L. Makowka, J. A. Falk, R. E. Falk

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

The purpose of this study was to determine the effect of an immunostimulative polymer, Copovithane (Cpv), plus antibiotics (netilmicin and clindamycin) in a murine model of fecal peritonitis. Cpv augments humoral immunity with little effect on T cells and is nontoxic. Cpv 100 mg/kg iv administered at the onset of sepsis increased median survival time (MST) by 40-55% over untreated controls. Four experiments were performed. Cpv in combination with antibiotics when given at the time of onset of sepsis was significantly more effective than antibiotics alone (MST 235 vs 105 hr, P < 0.05 at 144, 168, 192, 216 hr). In the second and third experiments Cpv alone and with antibiotics was administered 15 hr after the onset of sepsis. Cpv significantly augmented survival over controls in the second experiment (MST 87 vs 60 hr, P < 0.025 at 96 hr). Cpv plus antibiotics was significantly better than antibiotics alone in the third experiment (MST 111 vs 64 hr, P < 0.05 at 72 hr, P < 0.005 at 120 hr). In the final experiment, Cpv did not inhibit growth of 20 bacterial species in agar and liquid media. Cpv significantly enhances survival in murine fecal peritonitis even when administered after the onset of sepsis; furthermore Cpv plus antibiotics in established peritonitis produces longer survival than antibiotics alone. Synthetic immunomodulators such as Cpv could eventually play a significant role in the management of peritoneal infection in humans.

Original languageEnglish
Pages (from-to)494-500
Number of pages7
JournalJournal of Surgical Research
Volume38
Issue number5
DOIs
StatePublished - Jan 1 1985
Externally publishedYes

Fingerprint

Peritonitis
Polymers
Anti-Bacterial Agents
Survival
Sepsis
copovithane
Netilmicin
Clindamycin
Immunologic Factors
Humoral Immunity
Agar
T-Lymphocytes

ASJC Scopus subject areas

  • Surgery

Cite this

Enhanced survival in antibiotic-treated murine fecal peritonitis by administration of copovithane, a selective immunostimulative polymer. / Moffat, Frederick L; Clark, A. G.; Falk, M.; Teodorczyk-Injeyan, J. A.; Makowka, L.; Falk, J. A.; Falk, R. E.

In: Journal of Surgical Research, Vol. 38, No. 5, 01.01.1985, p. 494-500.

Research output: Contribution to journalArticle

Moffat, Frederick L ; Clark, A. G. ; Falk, M. ; Teodorczyk-Injeyan, J. A. ; Makowka, L. ; Falk, J. A. ; Falk, R. E. / Enhanced survival in antibiotic-treated murine fecal peritonitis by administration of copovithane, a selective immunostimulative polymer. In: Journal of Surgical Research. 1985 ; Vol. 38, No. 5. pp. 494-500.
@article{8335f49cb59e428eade29ddcc8ff4584,
title = "Enhanced survival in antibiotic-treated murine fecal peritonitis by administration of copovithane, a selective immunostimulative polymer",
abstract = "The purpose of this study was to determine the effect of an immunostimulative polymer, Copovithane (Cpv), plus antibiotics (netilmicin and clindamycin) in a murine model of fecal peritonitis. Cpv augments humoral immunity with little effect on T cells and is nontoxic. Cpv 100 mg/kg iv administered at the onset of sepsis increased median survival time (MST) by 40-55{\%} over untreated controls. Four experiments were performed. Cpv in combination with antibiotics when given at the time of onset of sepsis was significantly more effective than antibiotics alone (MST 235 vs 105 hr, P < 0.05 at 144, 168, 192, 216 hr). In the second and third experiments Cpv alone and with antibiotics was administered 15 hr after the onset of sepsis. Cpv significantly augmented survival over controls in the second experiment (MST 87 vs 60 hr, P < 0.025 at 96 hr). Cpv plus antibiotics was significantly better than antibiotics alone in the third experiment (MST 111 vs 64 hr, P < 0.05 at 72 hr, P < 0.005 at 120 hr). In the final experiment, Cpv did not inhibit growth of 20 bacterial species in agar and liquid media. Cpv significantly enhances survival in murine fecal peritonitis even when administered after the onset of sepsis; furthermore Cpv plus antibiotics in established peritonitis produces longer survival than antibiotics alone. Synthetic immunomodulators such as Cpv could eventually play a significant role in the management of peritoneal infection in humans.",
author = "Moffat, {Frederick L} and Clark, {A. G.} and M. Falk and Teodorczyk-Injeyan, {J. A.} and L. Makowka and Falk, {J. A.} and Falk, {R. E.}",
year = "1985",
month = "1",
day = "1",
doi = "10.1016/0022-4804(85)90067-8",
language = "English",
volume = "38",
pages = "494--500",
journal = "Journal of Surgical Research",
issn = "0022-4804",
publisher = "Academic Press Inc.",
number = "5",

}

TY - JOUR

T1 - Enhanced survival in antibiotic-treated murine fecal peritonitis by administration of copovithane, a selective immunostimulative polymer

AU - Moffat, Frederick L

AU - Clark, A. G.

AU - Falk, M.

AU - Teodorczyk-Injeyan, J. A.

AU - Makowka, L.

AU - Falk, J. A.

AU - Falk, R. E.

PY - 1985/1/1

Y1 - 1985/1/1

N2 - The purpose of this study was to determine the effect of an immunostimulative polymer, Copovithane (Cpv), plus antibiotics (netilmicin and clindamycin) in a murine model of fecal peritonitis. Cpv augments humoral immunity with little effect on T cells and is nontoxic. Cpv 100 mg/kg iv administered at the onset of sepsis increased median survival time (MST) by 40-55% over untreated controls. Four experiments were performed. Cpv in combination with antibiotics when given at the time of onset of sepsis was significantly more effective than antibiotics alone (MST 235 vs 105 hr, P < 0.05 at 144, 168, 192, 216 hr). In the second and third experiments Cpv alone and with antibiotics was administered 15 hr after the onset of sepsis. Cpv significantly augmented survival over controls in the second experiment (MST 87 vs 60 hr, P < 0.025 at 96 hr). Cpv plus antibiotics was significantly better than antibiotics alone in the third experiment (MST 111 vs 64 hr, P < 0.05 at 72 hr, P < 0.005 at 120 hr). In the final experiment, Cpv did not inhibit growth of 20 bacterial species in agar and liquid media. Cpv significantly enhances survival in murine fecal peritonitis even when administered after the onset of sepsis; furthermore Cpv plus antibiotics in established peritonitis produces longer survival than antibiotics alone. Synthetic immunomodulators such as Cpv could eventually play a significant role in the management of peritoneal infection in humans.

AB - The purpose of this study was to determine the effect of an immunostimulative polymer, Copovithane (Cpv), plus antibiotics (netilmicin and clindamycin) in a murine model of fecal peritonitis. Cpv augments humoral immunity with little effect on T cells and is nontoxic. Cpv 100 mg/kg iv administered at the onset of sepsis increased median survival time (MST) by 40-55% over untreated controls. Four experiments were performed. Cpv in combination with antibiotics when given at the time of onset of sepsis was significantly more effective than antibiotics alone (MST 235 vs 105 hr, P < 0.05 at 144, 168, 192, 216 hr). In the second and third experiments Cpv alone and with antibiotics was administered 15 hr after the onset of sepsis. Cpv significantly augmented survival over controls in the second experiment (MST 87 vs 60 hr, P < 0.025 at 96 hr). Cpv plus antibiotics was significantly better than antibiotics alone in the third experiment (MST 111 vs 64 hr, P < 0.05 at 72 hr, P < 0.005 at 120 hr). In the final experiment, Cpv did not inhibit growth of 20 bacterial species in agar and liquid media. Cpv significantly enhances survival in murine fecal peritonitis even when administered after the onset of sepsis; furthermore Cpv plus antibiotics in established peritonitis produces longer survival than antibiotics alone. Synthetic immunomodulators such as Cpv could eventually play a significant role in the management of peritoneal infection in humans.

UR - http://www.scopus.com/inward/record.url?scp=0022373338&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0022373338&partnerID=8YFLogxK

U2 - 10.1016/0022-4804(85)90067-8

DO - 10.1016/0022-4804(85)90067-8

M3 - Article

VL - 38

SP - 494

EP - 500

JO - Journal of Surgical Research

JF - Journal of Surgical Research

SN - 0022-4804

IS - 5

ER -